Enzyme Design, Expression, Purification, Functional Testing, and Pre-GMP Support for Genetic Medicine, Diagnostics, and RNA Workflows

Enzymes are the working machinery behind modern biotechnology.

They are not always the final therapeutic product. Often, they are the invisible tools that make the therapeutic, diagnostic, assay, or manufacturing process possible. A polymerase makes RNA. A capping enzyme matures it. A ligase joins fragments. A nuclease removes templates. A Cas enzyme edits, detects, or cleaves. A diagnostic enzyme generates signal. A restriction enzyme prepares DNA. A reverse transcriptase converts RNA into measurable nucleic acid. A custom catalytic protein becomes the quiet centre of an entire platform.

At Xoligo Biologics, we support Custom Recombinant Enzyme Development for companies building genetic medicine platforms, RNA workflows, molecular diagnostics, CRISPR systems, enzyme-powered assays, reagent products, synthetic biology tools, and pre-GMP biological components.

Xoligo is a Component CDMO for genetic medicine, diagnostics, and precision biomanufacturing. That means our enzyme work is not treated as generic recombinant protein production. We develop enzymes as functional components inside larger systems: RNA synthesis, CRISPR activity, molecular detection, diagnostic signal generation, assay control, process support, and manufacturing transfer.

A custom enzyme is not useful because it expresses.

It is useful because it performs.

From Cambridge, Xoligo supports program strategy, enzyme-use-case planning, customer interface, and development-roadmap design. From Montreal, we support nucleic acid workflows, RNA analytics, oligonucleotide development, and GMP-pathway planning. From Frederick, Maryland, we support recombinant protein expression, microbial fermentation, enzyme production, diagnostic components, and pre-GMP bridge material development.

This creates a balanced, lagom approach to enzyme development: enough structure to support serious progress, but not so much early burden that a program becomes slow before the science is ready.

Why Custom Recombinant Enzymes Matter

Many biotechnology companies begin with catalogue enzymes.

That is often sensible at the start. Catalogue enzymes are accessible, fast, and useful for proof-of-concept experiments. But as a program matures, the limits become more visible. The enzyme may not be optimized for the application. Supply may be inconsistent. The formulation may not fit the process. Activity may vary between lots. Residual impurities may affect performance. Documentation may be too thin. The company may not control the enzyme’s future availability. A critical workflow may depend on a reagent that was never designed for serious manufacturing.

Custom recombinant enzyme development helps solve that problem.

It gives companies a path toward enzyme supply that is better matched to the actual process, assay, diagnostic product, or genetic medicine platform.

The value may come from improved activity, cleaner impurity control, better stability, defined documentation, stronger lot comparability, lower endotoxin, better RNA compatibility, better storage, or simply greater control over a process-critical material.

For RNA companies, the enzyme may determine transcript quality.

For diagnostic companies, the enzyme may determine signal reliability.

For CRISPR companies, the enzyme may determine editing or detection performance.

For assay developers, the enzyme may determine whether a method is repeatable.

For pre-GMP programs, the enzyme may determine whether future transfer is practical.

This is not a small detail. It is often the hinge.

Enzyme Development for RNA Workflows

RNA manufacturing depends on a network of enzymes.

T7 RNA polymerase, SP6 polymerase, T3 polymerase, capping enzymes, methyltransferases, RNA ligases, DNA ligases, DNases, restriction enzymes, pyrophosphatases, RNase inhibitors, and cleanup enzymes may all influence RNA yield, integrity, capping efficiency, purity, and stability.

Xoligo supports recombinant enzyme development for RNA workflows by connecting expression, purification, activity testing, RNA compatibility, impurity control, and transfer-aware documentation.

The development question is not only whether the enzyme can be produced. The question is whether it improves or supports the RNA workflow.

A polymerase must generate RNA reproducibly. A capping enzyme must perform consistently under process conditions. A ligase must support the intended architecture, especially in circular RNA or structured RNA workflows. A DNase must remove template DNA without damaging the RNA. An RNase inhibitor must protect the product in a real process environment. A restriction enzyme must prepare templates cleanly enough for downstream transcription.

When an RNA process fails, the enzyme is often one of the first places to look. Poor transcript yield, fragmentation, incomplete capping, residual template, inconsistent performance, or unstable reactions may all connect back to enzyme quality.

Xoligo’s enzyme-development model is built around that connection.

Enzyme Development for Molecular Diagnostics

Diagnostics need enzymes that perform consistently under assay conditions.

A diagnostic enzyme may be used in qPCR, RT-qPCR, isothermal amplification, CRISPR diagnostics, clinical chemistry, biosensors, immunoassays, companion diagnostics, or research-use molecular testing. The enzyme must support signal, sensitivity, specificity, stability, and lot consistency.

Xoligo supports custom diagnostic enzyme development for polymerases, reverse transcriptases, nicking enzymes, ligases, nucleases, oxidases, dehydrogenases, peroxidases, phosphatases, CRISPR enzymes, and other functional assay proteins.

The diagnostic setting is different from open research. The enzyme must behave inside a defined assay format. It may need to tolerate inhibitors, buffers, dyes, probes, salts, stabilizers, lyophilization, room-temperature storage, or kit assembly. It may need to produce reliable signal after shipping. It may need to work with controls and calibrators. It may need to maintain performance across manufacturing lots.

That is why diagnostic enzyme development requires more than expression and purification.

It requires assay awareness.

A diagnostic enzyme is not just a protein with catalytic activity. It is part of a product experience: the user runs the assay, expects the signal, trusts the result, and wants the same performance next month.

Xoligo helps build enzymes with that end state in mind.

Enzyme Development for CRISPR Systems

CRISPR enzymes are recombinant enzymes with system-level requirements.

Cas9, Cas12, Cas13, nickases, dCas proteins, engineered nucleases, diagnostic Cas enzymes, and editing-adjacent proteins may all require development support around expression, activity, guide compatibility, impurity control, stability, and functional testing.

Xoligo supports custom recombinant CRISPR enzyme development for gene editing, molecular diagnostics, research tools, screening platforms, and pre-GMP component supply.

For CRISPR systems, enzyme performance depends on more than the enzyme alone. Guide RNA integrity, buffer conditions, target design, reporter oligos, delivery format, storage, endotoxin, residual host impurities, aggregation, and activity-assay design all affect the final result.

A Cas enzyme may look acceptable by purity and still perform weakly with the intended guide. A guide may be fine but paired with an enzyme that has lost activity. A diagnostic reporter may be the real bottleneck. A cell-based system may be distorted by endotoxin.

Xoligo helps customers avoid treating CRISPR enzyme development as a single-variable problem. The enzyme is developed as part of the full editing or detection system.

Host System Selection

Custom enzyme development begins with host-system selection.

E. coli may be the best choice for many enzymes because it is fast, scalable, and often productive. Yeast or Pichia may be preferable when secretion, folding, disulfide handling, or eukaryotic processing advantages matter. Mammalian expression may be appropriate for certain complex proteins, fusion enzymes, glycoprotein-adjacent components, or biologically sensitive constructs.

The right host depends on the enzyme.

A high-yield E. coli process is not useful if the enzyme is insoluble or inactive. A secreted yeast process is not useful if host proteases damage the product. A mammalian process is not useful if it creates unnecessary cost for an enzyme that could be made cleanly in microbial culture.

Xoligo supports host-system evaluation through construct review, expression strategy, purification expectations, functional requirements, impurity risks, and scale-up considerations.

This is where a bit of Swedish-style restraint helps. Do not overcomplicate too early. Do not underbuild when the molecule is already telling you it needs more care. Keep the system lagom: right-sized, practical, and based on evidence.

Construct Design and Expression Strategy

The construct determines much of the enzyme-development path.

Tag placement, codon optimization, domain boundaries, signal peptides, solubility tags, cleavage sites, fusion partners, mutations, truncations, linkers, and expression conditions can all affect enzyme yield, solubility, activity, and downstream purification.

Xoligo supports construct and expression strategy for custom enzymes, including early manufacturability review, expression-screen planning, host comparison, tag strategy, solubility assessment, and activity-preserving purification logic.

For enzymes, construct design should not only chase expression.

It should preserve function.

An N-terminal tag may interfere with activity. A C-terminal tag may affect stability. A solubility tag may improve expression but complicate downstream use. A cleavage step may reduce yield. A mutation may improve activity but reduce stability. A linker may preserve flexibility or create degradation risk.

These decisions are not cosmetic. They define the development path.

Fermentation and Upstream Development

Once the construct and host are selected, fermentation development turns expression into reproducible supply.

Xoligo supports microbial fermentation for custom recombinant enzymes, with attention to induction strategy, temperature, media, oxygen transfer, harvest timing, biomass, soluble expression, product stability, and downstream compatibility.

For enzyme programs, upstream development should be linked directly to downstream performance.

A process may produce high expression but poor activity. A lower-yield process may produce more soluble and functional enzyme. A harvest condition may preserve activity better than a more aggressive process. A fermentation change may reduce impurity burden or improve purification.

The best upstream process is not always the one with the highest apparent titre.

It is the one that produces the best usable enzyme.

Purification and Impurity Control

Enzyme purification must protect activity while removing enough impurity for the intended application.

This can involve affinity chromatography, ion exchange, hydrophobic interaction, size exclusion, polishing steps, buffer exchange, concentration, filtration, endotoxin reduction, residual DNA control, residual host cell protein control, nuclease removal, and activity-preserving formulation.

Xoligo supports purification strategy for custom enzymes used in RNA workflows, diagnostics, CRISPR systems, assays, and pre-GMP bridge material.

The purification plan depends on use case. An enzyme used in a research assay may need one level of purity. An enzyme used in an RNA manufacturing process may need stronger nuclease control. A Cas enzyme used in cell-based editing may need low endotoxin. A diagnostic enzyme may need stability and repeatable signal. A pre-GMP enzyme may need better documentation and lot comparability.

Purification should be clean, but not reckless. Over-polishing can reduce activity and recovery. Under-purifying can leave impurities that damage performance. Xoligo works toward the middle path: sufficient purity, preserved function, and development-stage realism.

Activity and Functional Assay Development

A custom enzyme must be tested by what it does.

Xoligo supports activity and functional assay development for recombinant enzymes, including catalytic assays, workflow-specific performance testing, lot comparison, stability-indicating activity testing, RNA compatibility assays, diagnostic signal assays, CRISPR functional assays, and application-specific readouts.

Activity testing can be used during expression screening, purification development, storage evaluation, formulation screening, lyophilization studies, comparability assessment, and tech transfer.

For custom enzymes, activity data is often more meaningful than purity alone.

A pure inactive enzyme is not a product.

A high-activity unstable enzyme is not a reliable component.

A functional enzyme with uncontrolled impurities may not support serious development.
A stable enzyme without documentation may not transfer cleanly.

The goal is balanced evidence: identity, purity, activity, stability, impurity control, and fit-for-purpose documentation.

Stabilization and Storage

Enzymes are vulnerable to loss of function during storage.

Buffer composition, pH, salt, reducing agents, stabilizers, glycerol, sugars, surfactants, freeze-thaw exposure, concentration, storage temperature, and lyophilization conditions can all affect activity.

Xoligo supports enzyme stabilization through buffer screening, freeze-thaw studies, storage-condition comparison, activity retention testing, lyophilization-readiness evaluation, and formulation support.

For diagnostic enzymes, stability may determine commercial practicality. For RNA workflow enzymes, stability may determine process reproducibility. For CRISPR enzymes, stability may determine editing consistency. For pre-GMP bridge material, stability may determine whether the material remains useful long enough to support studies and transfer.

An enzyme is not ready simply because it worked once.

It must keep working.

Pre-GMP Enzyme Development

Many companies need enzyme material that is more controlled than research-grade supply but not yet full GMP.

Xoligo supports pre-GMP recombinant enzyme development for genetic medicine, diagnostics, RNA workflows, CRISPR systems, and reagent platforms. This may include process summaries, batch records, analytical testing, activity data, impurity information, endotoxin or bioburden awareness, stability support, storage recommendations, and transfer notes.

Pre-GMP enzyme development is especially useful when the enzyme is critical to a platform. If the enzyme determines RNA quality, diagnostic signal, editing performance, or assay reliability, then it deserves serious development attention before the program moves further.

A good pre-GMP package helps the next team understand what was made, how it was made, how it performed, and what risks remain.

FAQ: Custom Recombinant Enzyme Development

1. What is custom recombinant enzyme development?

Custom recombinant enzyme development is the design, expression, purification, characterization, functional testing, stabilization, and documentation of enzymes built for a specific workflow, assay, diagnostic product, or genetic medicine platform.

2. What enzyme types can Xoligo support?

Xoligo can support RNA polymerases, capping enzymes, methyltransferases, ligases, nucleases, restriction enzymes, RNase inhibitors, polymerases, reverse transcriptases, diagnostic enzymes, Cas enzymes, oxidases, dehydrogenases, and custom catalytic proteins.

3. Why use a custom enzyme instead of a catalogue enzyme?

Catalogue enzymes are useful for early work, but custom enzymes may offer better control, supply consistency, documentation, stability, activity, impurity profile, and fit with the final process or diagnostic system.

4. Can Xoligo support enzymes for RNA manufacturing?

Yes. Xoligo can support enzymes used in IVT, capping, ligation, template cleanup, RNA protection, circular RNA workflows, and RNA analytical systems.

5. Can Xoligo support diagnostic enzymes?

Yes. Xoligo can support enzymes for qPCR, RT-qPCR, isothermal amplification, CRISPR diagnostics, biosensors, clinical chemistry, molecular diagnostics, and kit components.

6. Can Xoligo develop CRISPR enzymes?

Yes. Xoligo can support development of Cas enzymes and CRISPR-associated proteins, including activity testing, guide compatibility, impurity control, stability support, and pre-GMP documentation.

7. Which expression hosts are used for custom enzymes?

Depending on the enzyme, Xoligo may evaluate E. coli, yeast, Pichia, mammalian expression, or partner-supported systems. Host selection depends on folding, activity, purification, stability, and intended use.

8. How important is enzyme activity testing?

Activity testing is essential. A recombinant enzyme is only useful if it performs its intended function. Activity assays can support expression screening, purification development, stability, lot comparison, and tech transfer.

9. Can Xoligo reduce endotoxin in recombinant enzymes?

Yes. For E. coli-derived enzymes and sensitive applications, Xoligo can support endotoxin reduction strategy, testing, and process improvement.

10. Can custom enzymes be lyophilized or stabilized?

Some can. Xoligo can support stabilization and lyophilization-readiness studies to evaluate whether enzyme activity is preserved after storage, drying, reconstitution, or freeze-thaw stress.

11. Can Xoligo support pre-GMP enzyme material?

Yes. Xoligo can support pre-GMP bridge material for enzymes, including stronger documentation, analytical characterization, activity testing, impurity control, and transfer planning.

12. How does enzyme development support tech transfer?

A strong enzyme package can include construct information, expression process, purification method, analytical data, activity results, stability information, storage recommendations, and transfer notes for a future manufacturer or partner.

13. What is the most niche use case for custom enzyme development?

A specialised use case is developing a matched enzyme set for an RNA platform: T7 polymerase, capping enzyme, ligase, DNase, RNase inhibitor, and activity controls designed and characterized together so the RNA workflow behaves as a coordinated system rather than a collection of unrelated reagents.

Xoligo Biologics är en specialiserad Component CDMO för rekombinanta enzymer inom RNA-tillverkning, diagnostik, CRISPR-system och pre-GMP utveckling. Med ett lagom och tekniskt fokuserat arbetssätt kopplar Xoligo uttryck, fermentering, rening, aktivitetsanalys, endotoxinkontroll, stabilitet och dokumentation till enzymets verkliga användning. Målet är inte bara att producera ett protein, utan att skapa ett funktionellt enzym som fungerar pålitligt i kundens process, analys eller diagnostiska system.

Why Xoligo? Think about it.

Xoligo supports custom recombinant enzyme development with the full component system in mind.

We understand enzyme expression.
We understand microbial fermentation.
We understand RNA workflows.
We understand CRISPR systems.
We understand diagnostic assays.
We understand purification and impurity control.
We understand activity testing.
We understand stabilization.
We understand pre-GMP bridge material and transfer.

That matters because enzyme development is never only about producing a protein.

The enzyme must fit the process, preserve activity, remain stable, avoid hidden impurities, and support reliable downstream performance.

Xoligo helps customers build enzymes around that real use case.

From Enzyme Expression to Functional Infrastructure

Custom recombinant enzymes are part of the infrastructure of genetic medicine and diagnostics.

They make RNA.
They process nucleic acids.
They generate diagnostic signals.
They support CRISPR systems.
They power assays.
They enable synthetic biology workflows.

They become reference materials, controls, and process-critical components.

Xoligo Biologics helps companies move from enzyme idea to functional enzyme supply with development logic, analytical clarity, and transfer awareness.

Because the value of an enzyme is not that it can be expressed.

The value is that it can be trusted inside the system it was built to serve.